Clinical Trial Update: A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, and efficacy of MSDC-0602K in patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• MSDC-0602K (MSDC-0602K)

Snippet

Sponsor: Cirius Therapeutics, Inc. | Conditions: Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2020-08-21